Intelligence · Clinical Development
Pipeline search results
Programs matching “apatinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 29 pipeline programs matching "apatinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Lapatinib
GlaxoSmithKline
Neoplasms, Head and Neck
1 trial -
Lapatinib
Novartis Pharmaceuticals
Neoplasms, Breast
2 trials -
Lapatinib
Novartis Pharmaceuticals
Breast Neoplasms
1 trial -
lapatinib
GlaxoSmithKline
Neoplasms, Breast
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Gastric Adenocarcinoma
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Malignant Ascites
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer Metastatic
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Intrahepatic Cholangiocarcinoma
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Apatinib
Hospital Authority, Hong Kong
Soft Tissue Sarcoma, Adult, Stage II
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Thyroid
1 trial -
Apatinib
Chinese University of Hong Kong
Head and Neck Neoplasms
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Advanced Esophageal Squamous Carcinoma
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Apatinib Combined With SHR-1210 Injection
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Apatinib Mesylate +SHR-1210
Chinese University of Hong Kong
Hepatocellular Carcinoma
1 trial -
Apatinib mesylate tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Apatinib mesylate tablets
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Apatinib+ SHR-1210（Camrelizumab）
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Camrelizumab Plus Apatinib
Nanjing Zenshine Pharmaceuticals
Unresectable Hepatocellular Carcinoma (HCC)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.